Skip to main content

Advertisement

Open Peer Review Reports for: Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
12 Sep 2017 Submitted Original manuscript
20 Oct 2017 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 2
20 Oct 2017 Submitted Manuscript version 2
23 May 2018 Reviewed Reviewer Report - Fang Yang
31 May 2018 Reviewed Reviewer Report - Marzia Locatelli
28 Jun 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 3
28 Jun 2018 Submitted Manuscript version 3
10 Jul 2018 Reviewed Reviewer Report - Marzia Locatelli
8 Aug 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 4
8 Aug 2018 Submitted Manuscript version 4
8 Oct 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 5
8 Oct 2018 Submitted Manuscript version 5
10 Oct 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 6
10 Oct 2018 Submitted Manuscript version 6
Publishing
21 Oct 2018 Editorially accepted
6 Nov 2018 Article published 10.1186/s12885-018-4979-0

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement